Services

Our services are centred around intellectual property that can be registered. We protect innovation, design, and branding across all sectors of industry, and at all stages in the supply chain.

For each IP right we offer services covering strategic advice, pre-registration searches, registrations and renewals, oppositions and dispute resolution. We handle work throughout the world, working with local colleagues in over 100 countries.

Sectors

Our attorneys specialise in one or more sectors of industry, which enables them to provide quality advice with a commercial focus.

Our patent specialists have detailed understanding of the background technology, which ensures that your patent applications are prepared with the correct scope, reducing the likelihood of challenges from third parties and objections from the patent office.

They also advise whether other forms of protection would be more appropriate. Our brand specialists work with brand managers for leading brands and their advice is commercially focussed making sure that you get the best value from your budget.

2nd Feb 2024

Act NOW to retain your UK plant variety right “Brexit clone”

On 31 December 2020, the UK formally left the European Union (EU) single market and customs union – a process known informally as “Brexit”. Plant varieties which were protected by EU Community Plant Variety Rights (CPVRs) granted on or before that date were automatically afforded corresponding UK rights, called “Retained EU Plant Variety Rights” (aka UK plant variety right “Brexit clones”). The UK’s Animal & Plant Health Agency (APHA) advised that right holders wishing to keep their Retained EU Plant Variety Rights in force should, by 1 January 2024, provide details of a name and address of an agent in the UK together with a signed authorisation of agent form.

8th Feb 2021

Supplementary Protection Certificates (SPCs): Could the EU/UK trade deal have an impact on future SPC terms in Europe?

Just over one month into the “real Brexit” we have already seen two very high profile consequences of its impact on the pharmaceutical industry.Firstly, the UK’s medicine agency (the MHRA) approved the BioNTech/Pfizer and Oxford University/Astra Zeneca Covid-19 vaccines faster than the European Medicines Agency (EMA). Then, at the end of January, the European Commission threatened to prevent Covid-19 vaccines passing into Northern Ireland from Ireland. I am certainly not going to explore the potential political ramifications of this (swiftly withdrawn) threat of the EU Commission – twitter commentators have had their say on that – but I am interested in whether this unique situation on the island of Ireland could have future consequences for supplementary protection certificates (SPCs) in the UK and Europe.

1st Feb 2021

Brexit one month in

The UK has now left the EU, following a transition period that ended on 31 December 2020. In contrast to the position in a number of industries, the position in relation to IP rights has been relatively smooth. The UK Intellectual Property Office (UKIPO) has created and entered into its database the comparable rights based on EU trade mark and design registrations which were all in place as of Exit Day. The Office is continuing to work on comparable rights created from EU designations filed via the Madrid or Hague systems and appears to be making good progress. The UKIPO should be commended for this, particularly in view of the current working conditions.

Saved Staff
Staff member

Remove all

Saved profiles
Call +44 (0)20 7242 0901
Call +44 (0)1223 360 350
Call +49 (0) 89 206054 267
Call +(00) 31 70 800 2162

    X

    Register for notifications
    Enter your email address here to receive our monthly bulletin of IP news and developments.

    "*" indicates required fields

    Sector*
    I confirm that I have read Reddie & Grose's privacy notice and consent to my personal information being collected*
    Please read our privacy notice.